2,842
edits
Psychedelics: Difference between revisions
m
→Long Term Effects
mNo edit summary |
|||
| Line 73: | Line 73: | ||
Compared to the majority of other medications, the dangers linked with psychedelic use are considerably lower (See '''Figure 3'''). Research indicates that certain personality traits such as neuroticism will negatively influence long term outcomes<ref>'''Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression'''. Roseman L, Nutt DJ, Carhart-Harris RL. Front Pharmacol. 2018 Jan 17;8:974. doi: 10.3389/fphar.2017.00974. PMID: 29387009; PMCID: PMC5776504.</ref>, whereas traits like a willingness to surrender can have a positive impact<ref>'''Predicting Responses to Psychedelics''': A Prospective Study. Front. Pharmacol., 02 November 2018 | Compared to the majority of other medications, the dangers linked with psychedelic use are considerably lower (See '''Figure 3'''). Research indicates that certain personality traits such as neuroticism will negatively influence long term outcomes<ref>'''Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression'''. Roseman L, Nutt DJ, Carhart-Harris RL. Front Pharmacol. 2018 Jan 17;8:974. doi: 10.3389/fphar.2017.00974. PMID: 29387009; PMCID: PMC5776504.</ref>, whereas traits like a willingness to surrender can have a positive impact<ref>'''Predicting Responses to Psychedelics''': A Prospective Study. Front. Pharmacol., 02 November 2018 | ||
Sec. Neuropharmacology. Volume 9 - 2018 | [https://www.frontiersin.org/articles/10.3389/fphar.2018.00897/full https://doi.org/10.3389/fphar.2018.00897]</ref>. Clinically, provided that appropriate[[priming]], [[setting]] and [[integration]] are in place, there is substantial evidence supporting the safe and effective use of psychedelics in treating various conditions: | Sec. Neuropharmacology. Volume 9 - 2018 | [https://www.frontiersin.org/articles/10.3389/fphar.2018.00897/full https://doi.org/10.3389/fphar.2018.00897]</ref>. Clinically, provided that appropriate [[priming]], [[setting]] and [[integration]] are in place, there is substantial evidence supporting the safe and effective use of psychedelics in treating various conditions: | ||
* '''[[Depression]]''' - multiple meta-analyses results suggest that psychedelic-assisted therapy reduces [[MADRS]] with minimal [[Adverse Psychedelic Effects|adverse effects]]<ref>'''Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants'''. Nicole L. Galvão-Coelho, Psychopharmacology (Berl). 2021; 238(2): 341–354. Published online 2021 Jan 11. doi: 10.1007/s00213-020-05719-1. Accessed on 16th September 2022 via https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826317/pdf/213_2020_Article_5719.pdf</ref><ref>'''''A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy'''. Luoma, J. B., Chwyl, C., Bathje, G. J., Davis, A. K., & Lancelotta, R. (2020). Journal of Psychoactive Drugs, 1–11.'' doi:10.1080/02791072.2020.1769878. Accessed on 16th September 2022 via: https://pubmed.ncbi.nlm.nih.gov/32529966/ </ref>, relative to a comparable meta analysis of the effects of 21 traditional antidepressant drugs<ref>'''Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.''' Andrea Cipriani, MD. Published in the Lancet. February 21, 2018 DOI:<nowiki>https://doi.org/10.1016/S0140-6736(17)32802-7</nowiki></ref>. | * '''[[Depression]]''' - multiple meta-analyses results suggest that psychedelic-assisted therapy reduces [[MADRS]] with minimal [[Adverse Psychedelic Effects|adverse effects]]<ref>'''Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants'''. Nicole L. Galvão-Coelho, Psychopharmacology (Berl). 2021; 238(2): 341–354. Published online 2021 Jan 11. doi: 10.1007/s00213-020-05719-1. Accessed on 16th September 2022 via https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826317/pdf/213_2020_Article_5719.pdf</ref><ref>'''''A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy'''. Luoma, J. B., Chwyl, C., Bathje, G. J., Davis, A. K., & Lancelotta, R. (2020). Journal of Psychoactive Drugs, 1–11.'' doi:10.1080/02791072.2020.1769878. Accessed on 16th September 2022 via: https://pubmed.ncbi.nlm.nih.gov/32529966/ </ref>, relative to a comparable meta analysis of the effects of 21 traditional antidepressant drugs<ref>'''Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.''' Andrea Cipriani, MD. Published in the Lancet. February 21, 2018 DOI:<nowiki>https://doi.org/10.1016/S0140-6736(17)32802-7</nowiki></ref>. | ||